AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01476787
Drug: Rituximab-CHOP
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Trial: NCT01476787
Drug: Rituximab-CVP
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Trial: NCT01476787
Drug: Rituximab-Bendamustine
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Trial: NCT03413150
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
Trial: NCT03882762
Drug: Cebranopadol 200 μg tablet
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
Trial: NCT00471094
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT00471094
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT00471094
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT00471094
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Trial: NCT01877083
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 24 mg orally, once per day
Trial: NCT01582308
Drug: Sitagliptin 100 mg
RxNorm normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Trial: NCT01582308
Drug: Saxagliptin 5 mg
RxNorm normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Trial: NCT01582308
Drug: Vildagliptin 50 mg
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Trial: NCT01582308
Drug: Vildagliptin 50 mg BID
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
Trial: NCT00726687
Drug: indibulin
RxNorm normalized name: Indibulin
DrugBank: Indibulin (DB06169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indibulin, dose escalation, 400-600 mg taken twice every day
Trial: NCT01202435
Drug: Pregabalin controlled release, 82.5 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 82.5 mg controlled release tablet administered once daily for four days.
Trial: NCT01202435
Drug: Pregabalin immediate release, 25 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg immediate release capsules administered three times daily for four days
Trial: NCT05740098
Drug: Nicotine Replacement Therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patches and gum/lozenge provided together for dual therapy
Trial: NCT04401137
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate
Trial: NCT02161705
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
Trial: NCT02161705
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 0.8 mL/kg of normal saline administered
Trial: NCT01229150
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
Trial: NCT01229150
Drug: AZD6244 + Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
Trial: NCT01032213
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
Trial: NCT03115697
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose 20 mL
Trial: NCT03115697
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 BD
Trial: NCT01782222
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)
Trial: NCT02901379
Drug: Atorvastatin 80mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 80MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will be given atorvastatin 80mg for two weeks
Trial: NCT02901379
Drug: Atorvastatin 10mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
Trial: NCT00725322
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
Trial: NCT01318369
Drug: Diazepam
RxNorm normalized name: Diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Trial: NCT03517319
Drug: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT03517319
Drug: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT03517319
Drug: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT03517319
Drug: Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01573663
Drug: Ambroxol and Levodropropizine
RxNorm normalized name: clenbuterol and ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
Trial: NCT01257087
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
Trial: NCT02861040
Drug: Vincristine Sulfate Liposome
RxNorm normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02861040
Drug: Volasertib
RxNorm normalized name: Volasertib
DrugBank: Volasertib (DB12062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01573663
Drug: Ambroxol
RxNorm normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol HCl 30mg, PO, single dose
Trial: NCT01573663
Drug: Levodropropizine
RxNorm normalized name: levodropropizine
DrugBank: Levodropropizine (DB12472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodropropizine 60mg, PO, single dose
Trial: NCT00730691
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated vortioxetine immediate release tablets
Trial: NCT00730691
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overencapsulated duloxetine capsules
Trial: NCT00147524
Drug: quinapril
RxNorm normalized name: Quinapril
DrugBank: Quinapril (DB00881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00396175
Drug: MK0906, finasteride / Duration of Treatment : 48 Weeks
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01152645
Drug: ARQ 197
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally twice daily administration of ARQ 197
Trial: NCT01728181
Drug: Tivozanib
RxNorm normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
Trial: NCT01728181
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/day for 28 day cycle. No rest period.
Trial: NCT00002508
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002508
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02161679
Drug: IMMU-132 plus Carboplatin infusion
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02490293
Drug: Cephalosporin
RxNorm normalized name: Cephalosporin
DrugBank: Cephalosporin analog (DB02136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.
Trial: NCT00406302
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m², day 1,22
Trial: NCT00406302
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg/m², d1,2,22,23
Trial: NCT00406302
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
Trial: NCT02200562
Drug: ipilimumab and dabrafenib
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04505098
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 g by mouth twice daily for at least 6 months
Trial: NCT00663169
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 mg intravenous infusion 50 mL over 30 minutes.
Trial: NCT02705989
Drug: BMS-986195
RxNorm normalized name: BMS-986195
DrugBank: Branebrutinib (DB15347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified day
Trial: NCT04238702
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10 MG 7 days intervention period
Trial: NCT04238702
Drug: Losartan 50Mg Tab
RxNorm normalized name: LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50 MG 7 days intervention period
Trial: NCT03601975
Drug: Gemcitabine/Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
Trial: NCT04129554
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
Trial: NCT04129554
Drug: JNJ-56136379
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
Trial: NCT03505021
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 1 mg capsule for oral administration
Trial: NCT02153645
Drug: 240mg Amantadine HCl ER tablets
RxNorm normalized name: amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01239004
Drug: Colesevelam
RxNorm normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
Trial: NCT03505021
Drug: Placebo for levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule for oral administration
Trial: NCT04129554
Drug: Entecavir (ETV) monohydrate
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT04129554
Drug: Tenofovir disoproxil fumarate (TDF)
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT04129554
Drug: Tenofovir alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Trial: NCT02101853
Drug: Asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM or IV
Trial: NCT02101853
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT and IV or SC
Trial: NCT02101853
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT02101853
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02101853
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02101853
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02101853
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01841333
Drug: PF-04449913
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg given orally
Trial: NCT02831673
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Trial: NCT02831673
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
Trial: NCT02831673
Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
Trial: NCT00874120
Drug: Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg
RxNorm normalized name: guaifenesin / phenylephrine hydrochloride Extended Release Oral Tablet
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
Trial: NCT00496821
Drug: ALN-RSV01
RxNorm normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00477165
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg/day for 4 weeks, then 40 mg/day for 4 weeks
Trial: NCT02153645
Drug: 320mg Amantadine HCl ER tablets
RxNorm normalized name: amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02101853
Drug: Thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02101853
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02101853
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02879305
Drug: Daprodustat
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
Trial: NCT02879305
Drug: rhEPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
Trial: NCT04039698
Drug: Velpatasvir/Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks